Johnson & Johnson signs up Emergent BioSolutions to support COVID-19 vaccine manufacturing
CDMO to supply drug substance manufacturing services and reserve capacity for possible commercial production next year
Johnson & Johnson has signed a deal with contract development and manufacturing organisation (CDMO) Emergent BioSolutions to support efforts to manufacture its lead investigational COVID-19 vaccine candidate, the US pharmaceutical company has announced.
Under the terms of the agreement, valued at around USD 135 million, J&J will expand drug substance capacity related to the vaccine candidate.
Emergent will provide drug substance manufacturing services with its molecule-to-market CDMO offering later this year and will also reserve capacity to support commercial manufacturing of the vaccine candidate net year should it gain regulatory approval.
Large-scale manufacturing of drug substance for the vaccine will be done at Emergent’s Baltimore Bayview facility, which was designed for rapid mass-production of vaccines and treatments during public health emergencies.
J&J has already begun preparations for clinical vaccine production at its facility in Leiden, the Netherlands, and plans to start Phase 1 human trials of its vaccine candidate in September.
The firm said it will begin vaccine production ‘at risk’ to support the trials and has committed to bringing an affordable vaccine to market on a not-for-profit basis for emergency pandemic use.
“We have set a high bar,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, J&J. “Johnson & Johnson has committed to rapidly produce and supply more than one billion doses of a safe and effective vaccine globally. Our collaboration with Emergent is proof that we are moving quickly to deliver on that promise.”
J&J said it is also aiming to rapidly scale up vaccine manufacturing globally, including increasing capacity outside the US, to support potential rapid production of a vaccine.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance